Rein Therapeutics, Inc. (RNTX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Rein Therapeutics, Inc. (RNTX) Healthcare & Pipeline Overview

Rein Therapeutics, a clinical-stage biopharmaceutical firm, is dedicated to the advancement of cancer treatments, primarily through its ALRN-6924 candidate. This cell-permeating peptide targets the p53 pathway in tumors, positioning the company within the competitive oncology therapeutics market, albeit with significant development and regulatory hurdles.

What Is the Investment Thesis for RNTX?

Rein Therapeutics presents a high-risk, high-reward investment opportunity typical of clinical-stage biopharmaceutical companies. The core value driver is ALRN-6924, targeting wild-type p53 cancers, a substantial market if clinical trials prove successful. Upcoming Phase 2 trial results will be a critical catalyst. The company's $21.9M market cap reflects the inherent uncertainty, but positive data could lead to significant appreciation. However, potential risks include trial failures, regulatory hurdles, and the need for additional funding, all of which could dilute shareholder value. Investors should closely monitor clinical trial progress and cash runway.

Based on FMP financials and quantitative analysis

RNTX Key Highlights

Market capitalization of $21.9M reflects the company's early stage and associated risks.

• ALRN-6924 is the lead product candidate, targeting a potentially large market of cancers with wild-type p53.
• The company has a small team of 11 employees, indicating a lean operational structure.
• The company does not currently offer a dividend, consistent with its focus on reinvesting in research and development.
• Beta of 1.40 suggests higher volatility compared to the overall market.

Who Are RNTX's Competitors?

RNTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are RNTX's Key Strengths?

Novel approach to cancer treatment targeting wild-type p53.

• Lead product candidate, ALRN-6924, in clinical development.
• Experienced management team with expertise in drug development.

What Are RNTX's Weaknesses?

Limited financial resources compared to larger pharmaceutical companies.

• Dependence on the success of ALRN-6924.
• Small team size may limit operational capacity.

What Could Drive RNTX Stock Higher?

Phase 2 clinical trial results for ALRN-6924 in specific cancer types.

• Potential strategic partnerships with larger pharmaceutical companies.
• Progress in expanding the application of ALRN-6924 into additional cancer types.
• Development of companion diagnostics to identify patients who are most likely to respond to ALRN-6924.

What Are the Key Risks for RNTX?

Listing risk — at $0.7825 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.

• Financial-distress signal — its Altman Z-Score of -9.05 sits in the distress zone (elevated bankruptcy risk).
• Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
• Clinical trial failures for ALRN-6924.
• Regulatory hurdles in obtaining approvals for ALRN-6924.
• Competition from other oncology therapeutics.
• Need for additional funding to support clinical development and commercialization.
• Intellectual property challenges.

What Are the Growth Opportunities for RNTX?

• Expansion into New Cancer Types: Rein Therapeutics has the opportunity to expand the application of ALRN-6924 into additional cancer types beyond its current focus. This would involve conducting further clinical trials to demonstrate efficacy in these new indications. The market size for each new cancer type could be substantial, potentially adding significant value to the company. Timeline: Ongoing, contingent on clinical trial results.
• Strategic Partnerships: Forming strategic partnerships with larger pharmaceutical companies could provide Rein Therapeutics with access to additional funding, resources, and expertise. This could accelerate the development and commercialization of ALRN-6924. The value of such partnerships could range from millions to billions of dollars, depending on the terms of the agreement. Timeline: Ongoing.
• Geographic Expansion: Expanding into new geographic markets, such as Europe and Asia, could provide Rein Therapeutics with access to a larger patient population. This would involve obtaining regulatory approvals in these regions and establishing distribution networks. The market size for oncology therapeutics in these regions is substantial. Timeline: 3-5 years, contingent on regulatory approvals.
• Development of Companion Diagnostics: Developing companion diagnostics to identify patients who are most likely to respond to ALRN-6924 could improve treatment outcomes and increase market penetration. This would involve developing diagnostic tests that can detect the presence of wild-type p53 in tumors. Timeline: 2-3 years.
• Exploration of New Therapeutic Applications: Exploring new therapeutic applications for ALRN-6924 beyond cancer could open up new market opportunities. This would involve conducting preclinical and clinical studies to evaluate the potential of ALRN-6924 in other diseases. Timeline: 5+ years.

What Are RNTX's Competitive Advantages?

• Patented technology related to ALRN-6924.
• Expertise in developing cell-permeating peptides.
• Focus on a specific niche within the oncology market (wild-type p53 cancers).

What Does RNTX Do?

Rein Therapeutics, Inc., established on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, is a clinical-stage biopharmaceutical company headquartered in Austin, TX. The company is dedicated to the development and commercialization of innovative therapeutics aimed at treating cancer and other diseases. Rein Therapeutics' primary focus centers around its lead product candidate, ALRN-6924, a cell-permeating peptide designed to disrupt the interaction between p53 suppressors MDM2 and MDMX and the tumor suppressor p53. This disruption reactivates tumor suppression in cancers characterized by non-mutant, or wild-type, p53. The company's approach targets a significant portion of cancer patients who have wild-type p53, offering a potentially more effective treatment option. Currently, Rein Therapeutics is navigating the clinical trial phases, seeking to demonstrate the safety and efficacy of ALRN-6924 across various cancer types. The company's long-term success hinges on positive clinical trial outcomes, regulatory approvals, and successful commercialization strategies within the highly competitive pharmaceutical landscape. With a small team of 11 employees, Rein Therapeutics operates with a focused and agile approach to drug development.

What Products and Services Does RNTX Offer?

• Develop novel therapeutics for the treatment of cancer.
• Focus on reactivating tumor suppression in non-mutant p53 cancers.
• Develop cell-permeating peptides that disrupt the interaction of p53 suppressors.
• Conduct clinical trials to evaluate the safety and efficacy of their product candidates.
• Seek regulatory approvals for their therapeutics.
• Commercialize their approved therapeutics.

How Does RNTX Make Money?

• Develop and patent novel therapeutic compounds.
• Conduct clinical trials to demonstrate safety and efficacy.
• Seek regulatory approval from agencies like the FDA.
• Potentially partner with larger pharmaceutical companies for commercialization.

What Industry Does RNTX Operate In?

Rein Therapeutics operates within the competitive oncology therapeutics market, characterized by rapid innovation and intense regulatory scrutiny. The industry is driven by the increasing prevalence of cancer and the demand for more effective and targeted treatments. Rein Therapeutics' focus on wild-type p53 cancers positions it within a niche segment, potentially offering a competitive advantage if ALRN-6924 proves successful. However, the company faces competition from larger pharmaceutical companies with greater resources and established pipelines.

Who Are RNTX's Key Customers?

• Hospitals and cancer treatment centers.
• Oncologists and other healthcare professionals.
• Patients with cancer.

Company Profile

Rein Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Austin, US. The company is led by CEO James Brian Windsor. RNTX has traded publicly since 2017.

Rein Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -9.05 places it in the distress zone, a signal of elevated financial risk.

Key Financial Metrics

Its free cash flow yield is -73.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.40 means current liabilities exceed short-term assets, a liquidity point worth watching.

RNTX Valuation & Market Position

With a $21.9M market cap, Rein Therapeutics, Inc. sits in the micro-cap segment of the market. Analyst price targets span from $6.00 to $6.00, with a consensus of $6.00. At the current price of $0.78, that implies approximately 667% upside potential. Relative to its peer group, RNTX's quantitative score of 28/100 is below the peer average of 42/100.

Rein Therapeutics, Inc. has missed Wall Street's EPS estimate in 4 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 39.6% below estimates on average.

Wall Street analysts project Rein Therapeutics, Inc. revenue of about $69.8M for fiscal 2026, with EPS near $-0.46.

Over the past six months, Rein Therapeutics, Inc. insiders filed 6 SEC Form 4 transactions — 0 sales and 6 purchases. On net that is roughly 222K shares acquired (about $250K) — insiders putting money in tends to read as conviction.

RNTX Financials

RNTX Latest News

RNTX Analyst Consensus

RNTX MoonshotScore

Common Questions About RNTX (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources